Encompass Health (EHC) CMO reports 10,798-share equity awards in Form 4 filing
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Encompass Health Corp Chief Medical Officer Elissa Joy Charbonneau reported stock awards in the company’s common stock. On February 18, 2026, she acquired 8,914 shares at $0.00 per share as an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan. On February 19, 2026, she acquired an additional 1,884 shares of restricted stock at $0.00 per share upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. Following these grants, she directly owned a total of 22,756.061 shares of Encompass Health common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Charbonneau Elissa Joy
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Encompass Health Common Stock | 1,884 | $0.00 | -- |
| Grant/Award | Encompass Health Common Stock | 8,914 | $0.00 | -- |
Holdings After Transaction:
Encompass Health Common Stock — 22,756.061 shares (Direct)
Footnotes (1)
- This issuance of restricted stock is the result of the satisfaction of performance criteria set out in the terms of a performance share unit award made on February 23, 2023. Annual award of restricted stock pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.
FAQ
What insider transactions did Encompass Health (EHC) report for Elissa Joy Charbonneau?
Encompass Health reported that Chief Medical Officer Elissa Joy Charbonneau acquired restricted stock in two grants totaling 10,798 shares. These were reported as awards at $0.00 per share rather than open-market purchases or sales, reflecting equity compensation rather than trading activity.
Were the Encompass Health (EHC) insider stock awards open-market purchases?
These transactions were not open-market purchases. Both entries use transaction code “A” for grants or awards at $0.00 per share. They reflect equity compensation awards, including a performance-based conversion and an annual restricted stock grant, rather than discretionary buying or selling.